Seegene is playing a critical role in developing effective testing solution to mitigate the spread of rapidly mutating COVID-19 and variants.
Full screening for SARS-CoV-2 and variants
including the five notable mutations in S gene
Identification of major SARS-CoV-2 variants of
concern and highly conserved region in RdRP gene
Identification of major SARS-CoV-2
variants of concern
Accurate detection of SARS-CoV-2
Delta variants
Accurate detection of SARS-CoV-2
Delta & Lambda variants
Accurate detection of SARS-CoV-2
Lamda & Mu variants
Accurate detection of SARS-CoV-2
and Omicron-specific mutations
Seegene utilizes bioinformatics (SG-Insilico™) to monitor newly emerging SARS-CoV-2 sequence information on a regular basis and design optimized diagnostic assay.
Allplex™ 2019-nCoV Assay
Allplex™ SARS-CoV-2 Assay
Allplex™ SARS-CoV-2/FluA/FluB/RSV Assay
Allplex™ SARS-CoV-2 Master Assay
Allplex™ SARS-CoV-2 Variants I Assay
Allplex™ SARS-CoV-2 Variants II Assay
Novaplex™ SARS-CoV-2 Variants IV Assay (RUO)
Novaplex™ SARS-CoV-2 Variants V Assay (RUO)
Novaplex™ SARS-CoV-2 Variants VI Assay (RUO)
Novaplex™ SARS-CoV-2 Variants VII Assay (RUO)
Allplex™ SARS-CoV-2 fast PCR Assay
Allplex™ SARS-CoV-2 Master Assay can be used alone or expanded to syndromic test with respiratory essential panel for common respiratory infections, including influenza A and B, metapneumovirus, parainfluenza virus 1/2/3/4, adenovirus, rhinovirus A/B/C and respiratory syncytial virus A/B, to provide more insights for diagnosis of symptomatic patients especially with the emerging SARS-CoV-2 variants.
Allplex™ SARS-CoV-2/FluA/FluB/RSV Assay is designed to detect and differentiate between SARS-CoV-2, influenza A, influenza B and RSV
for primary screening during the upcoming flu season.
- The endogenous and exogenous internal controls are designed to verify the entire process from sample collection to nucleic acid extraction and PCR steps
- The endogenous internal control enables validating correct sampling for self-collected specimens
Multiplex real-time PCR with high sensitivity and specificity by utilization of Seegene’s proprietary technologies
Detecting N, S, RdRP and/or E target genes of SARS-CoV-2 to minimize the risk of genetic variations and allow high accuracy
No cross-reactivity confirmed with respiratory pathogens including SARS, MERS and SARS-related viruses
Seegene’s automated molecular diagnostic system allows a unique streamlined workflow with quick and simple steps for detection of COVID-19.
Watch the videos that can show you the outstanding features and benefits of Seegene’s COVID-19 assays.
With Seegene’s core technologies and proprietary know-hows, enhance your MDx products with incomparable performance and usability.
Enables rapid designing of high multiplex oligos using Seegene-developed algorithms and confidential variables.
Allows the implementation of high multiplex diagnostics with unparalleled specificity using Seegene’s unique primer structure.
Achieves accurate target signals by independently controlling multiple target signals for primer and probe annealing temperatures.
Broadens capacity for high multiplex target detection & quantification by enabling analysis of multiple Ct values in a single detection channel.
Enables accurate reporting of target’s positive or negative results through Seegene’s proprietary signal processing algorithms.